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Abstract: The combination of cytotoxic therapies and anti-angiogenic agents is emerging 
as a most promising strategy in the treatment of malignant tumors. However, the timing 
and sequencing of these treatments seem to play essential roles in achieving a synergic 
outcome. Using a mathematical modeling approach that is grounded on available 
experimental data, we investigate the spatial and temporal targeting of tumor cells and 
neovasculature with a nanoscale delivery system. Our model suggests that the 
experimental success of the nanoscale delivery system depends crucially on the trapping 
of chemotherapeutic agents within the tumor tissue. The numerical results also indicate 
that substantial further improvements in the efficiency of the nanoscale delivery system 
can be achieved through an adjustment of the temporal targeting mechanism. 
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1. Introduction 
 
The growth of a tumor beyond an avascular state requires the expansion of its vascular 
network, a process which is realized through the recruitment of host vasculature 
(angiogenesis) and/or vasculogenesis. Although the inhibition of tumor angiogenesis 
represents a promising approach to the treatment and control of cancers, recent preclinical 
studies have suggested that currently available anti-angiogenic strategies are unlikely to 
produce significant therapeutic gains on their own, but rather will need to be used in 
combination with conventional treatments to achieve maximal benefit (Jain 2001, 2005). 
To date, however, experimental studies combining anti-angiogenic and cytotoxic 
therapies have shown mixed results (Murata et al. 1997, Bello  et al. 2001, Ma et al. 
2001, Rofstad et al. 2003, Zips et al. 2003, Fenton et al. 2004, Ma and Waxman 2008), 
perhaps in part due to differences in scheduling and sequencing of these modalities.  
 
Currently, one major challenge to the successful combination of conventional and anti-
angiogenic therapies is that the administration of an anti-angiogenic agent impairs blood 
flow inside the tumor microenvironment, thus preventing efficient delivery of the 
chemotherapeutic agent. This difficulty must also be reconciled with the emerging notion 
of “normalization” of tumor vasculature. The tumor vascular network that arises from 
abnormal angiogenesis is spatially and temporally heterogeneous with defective 
endothelium, basement membrane, and pericyte coverage, and is characterized by 
interstitial hypertension, hypoxia, and acidosis (Jain 2005). Although high global blood 
flow is a feature of many tumors, the irregular tumor vasculature is very inefficient at 
delivering nutrients, as well as chemotherapeutic drugs, to malignant cells. It has been 
suggested (Jain 2001, 2005) that the judicious administration of certain anti-angiogenic 
agents can structurally and functionally “normalize” the abnormal tumor vascular 
network, rendering the vasculature more conducive to the efficient delivery of both drugs 
and nutrients to the targeted cancer cells. This transient normalization is characterized by 
more regular vascular morphology and basement membrane structure, increased pericyte 
coverage, and decreased hypoxia and interstitial fluid pressure. Recent experimental and 
clinical studies have shown that blockade of VEGF (vascular endothelial growth factor) 
signaling, passively prunes some of the immature and leaky vessels of tumors, and 
actively remodels the remaining vasculature, resulting in a more normalized network 
(Tong et al. 2004, Willett et al. 2004, Winkler et al. 2004). Even more recently, it has 
been shown that creation of perivascular nitric oxide gradients may also result in the 
normalization of tumor vasculature (Kashiwagi et al. 2008). 
 
A severe limitation to taking advantage of a normalized vascular network is that such a 
state lasts for only a short period of time (Winkler et al. 2004, Franco et al. 2006, 
Hormigo et al. 2007, Batchelor et al. 2007). After the transient window of vascular 
normalization has passed, both tumor oxygenation and penetration of chemotherapeutic 
drugs decrease. The ensuing hypoxia activates hypoxia-inducible factor (HIF)-1, up-
regulating many genes involved in angiogenesis, and renders tumor cells resistant to 
chemotherapeutic agents (Pugh et al. 2003, Bristow and Hill 2008). Thus, spatial and 
temporal tumor targeting play a critical role in devising efficient combination therapeutic 
strategies. 
 
Sengupta et al. (2005) recently designed a novel delivery system (termed a nanocell) 
comprising a nanoscale pegylated-lipid envelope coating a nuclear nanoparticle. A 
chemotherapeutic agent (doxorubicin) is conjugated to the nanoparticle and an anti-
angiogenic agent (combretastatin) is trapped within the lipid envelope. The nanocells 
extravasate into the tumor through the enhanced permeation and retention (EPR) effect 
(Yuan et al. 1994, Sengupta and Sasisekharan 2007) (see Fig. 1), a consequence of the 
highly leaky nature of tumor vasculature (having pores with diameters of 400-600nm). 
This is clearly visible in Figure 1 by the preferential accumulation of nanocells (labeled 
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with quantum dots) in the tumor compared to other vascularised tissues: the nanocells are 
spatially restricted within normal vasculature but extravasate out from the tumor 
vasculature (Sengupta et al. 2007). The rapid release of the anti-angiogenic agent results 
in at least a partial collapse of the network of tumor blood vessels. The entrapped 
nanoparticles then slowly release the chemotherapeutic drugs, which remain localized due 
to the disruption of the nearby vasculature. Sengupta et al. (2005) compared the effects of 
sequential drug delivery using nanocells with several conventional approaches on mice 
with B16:F10 melanomas or Lewis lung carcinomas. Animals treated with nanocells 
containing both drugs showed a better tumor response than any of the other treatment 
groups.  
 
While the nanoscale delivery approach outlined above produced a markedly improved 
effect on tumor control, there remains potential for further refinement of the release 
kinetics.  This motivated us to adapt a mathematical model (Kohandel et al., 2007), which 
incorporates tumor cells, vascular network, as well as their interplay, and the effects of 
chemotherapy and anti-angiogenic therapy to the experimental system studied by 
Sengupta et al.  The details of this model are described in Sec. 2; Sec. 3 discusses the 
mechanism for the synergistic effect of the nanocell treatment suggested by our model, 
and how it may be possible to improve the efficiency of the nanocell treatment even 
further. 
2. Methods 
In order to devise an efficient combination of cytotoxic and anti-angiogenic therapies, it 
is essential to take into consideration the mechanism and timing of tumor vessel response 
to anti-angiogenic agents, as well as the coupling between tumor growth, the vascular 
network, and response to cytotoxic agents. We have recently developed a mathematical 
model that incorporates tumor cells and the vascular network, as well as their interactions, 
and applied it to study the combination of anti-angiogenic and radiotherapeutic treatments 
(Kohandel et al. 2007). The experimental data of Winkler et al. (2004) were used to 
estimate the model parameters and validate its predictions. The results indicated that 
application of anti-angiogenic therapy, which temporarily results in better delivery of 
therapeutic agents, in advance of radiotherapy is the most effective approach, consistent 
with the experimental results.  
 
In this paper, we build upon a previous mathematical model (Kohandel et al. 2007) by 
including the effects of chemotherapy and the sequential release kinetics of nanocells. In 
formulating the model our guiding principle is to make minimal assumptions about the 
underlying phenomenology of cellular processes, while incorporating the essential 
features of the experiments by Sengupta et al. (2005). A key feature of the latter is the 
release kinetics of the drugs in nanocells: combretastatin has a rapid release (reaching 
significant levels within 12 h), while doxorubicin releases more slowly extending over 15 
days (compared to approximately 4 days for liposomes). Our mathematical model 
incorporates this temporal targeting profile and allows complete control over other 
possible factors contributing to the increased effectiveness of the nanocell treatment, such 
as differences in the total amount of drugs delivered to the cancer cells. Thus, we can 
directly test and further investigate the temporal targeting mechanism proposed by 
Sengupta et al. (2005). 
 
2.1 Tumor cells and vascular network 
 
Following previous studies of tumor growth, we model the density of cancer cells (at 
position x at time t) by a spatio-temporal field n(x,t) according to a variant of the Fisher 
equation (below). The novel aspect of our approach is to similarly introduce a field m(x,t) 
to model the density of blood vessels. This circumvents accounting for the precise nature 
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of blood flow, and as demonstrated earlier (Kohandel et al. 2007), the key features of the 
interplay between growth and blood supply can be captured the evolution equations  
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For simplicity, the above equations are presented in dimensionless form. They are related 
to the corresponding dimension-full equations via the transformations t  t , 
x   / D1 x , and n  n / nlim (Kohandel et al. 2007), where   is the net proliferation 
rate, D1 is the diffusion coefficient of tumor cells, and nlim is the “carrying capacity” for 
tumor cells. 
 
For 0~1  , Eq. 1.1 is the (dimensionless) Fisher equation, which has two fixed points; an 
unstable fixed point at 0* n  (no population at all), and a stable fixed point at 1* n  
(where the population saturates to the carrying capacity). In the absence of the nonlinear 
term, i.e., for the simple exponential form and 0~1  , integrating both sides of Eq. 1 
leads, for a constant diffusion coefficient, to a simple exponential increase in the number 
of cells. The growth of a tumor beyond an avascular state (up to a maximum size of about 
1-2 mm in diameter) requires the development of a vascular network. The additional term 
mn1
~  in Eq. 1 indicates that tumor growth is enhanced by the presence of vasculature. 
Mathematically, this results in a stable fixed point at *1
* ~1 mn  , see below.  
 
 
Following Kohandel et al. (2007) 1, we use Eq. 1.2 to take into account the heterogeneous 
tumor vasculature. This coarse-grained model, instead of the exact pattern of vessels, 
produces islands of vascular and non-vascular networks. For  0~2  , and setting 1~  , 
3~  , and 2~  , we obtain two stable fixed points for *m  at 0 and 1, and one unstable 
one at ½. Starting from a random (positively distributed and close to zero) initial 
configuration for )0,(xm , Eq. 1.2 produces randomly distributed islands of 1m  
(vascular) and 0m  (non vascular). The last term in Eq. 1.2, nm2~ , represents the 
effect of tumor cells on the development of vessels. We assume that the tumor cells 
produce the proangiogenic cytokines, leading to the extension of the vascular network; in 
our phenomenological approach, we assume that the higher density of cancer cells creates 
higher vascular density. In fact, a non-zero 2
~  shifts the stable fixed points to 
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For example, for 1.1~1   and 9.0~2   (obtained from fits to experimental data, see the 
results and discussion section), 97.1,02.0* m . Thus the fixed point at 1 moves to a 
higher value, indicating that the tumor vascular density is higher than in the 
corresponding normal tissue. This increased value will also be utilized in modeling of the 
                                                 
1 Equations (6) and (8) of Kohandel et al. (2007) contain typos in the interaction terms 1K (x, t)c  
and ˜ 1K (x, t)c  which, in the notation of Kohandel et al. (2007), should in fact read 1m(x, t)c  
and ˜ 1m(x, t)c , respectively. 
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poor delivery characteristics of the tumor vasculature, as well as the effect of anti-
angiogenic therapy, see below.  
 
2.2 Delivery of nanocells and liposomes 
 
Following the same strategy, we model the spatio-temporal variations of liposomes and 
nanocells by concentration fields ),( txCi , the discrete index i labeling the drug 
administration at time ti. The permeation of nanoparticles within a tumor depends on their 
sizes; large nanoparticles of the order of 100 nm (which is the case in Sengupta et al. 
2007 experiments) appear to stay close to the vasculature (Perrault et al. 2009). Hence, 
we assume that diffusion of liposomes and nanocells within the tissue surrounding the 
tumor, as well as re-absorption of these particles into the blood vessels, can be neglected. 
The evolution of the field ),( txCi  is then modeled by the dimensionless equation, 
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The function )(ti  represents the (average) concentration of the liposomes and nanocells 
in the blood vessels (see Sec. 2.4). The tumor vasculature is structurally and functionally 
abnormal, and the vessels are very inefficient at delivering nutrients and 
chemotherapeutic drugs. This poor delivery could be due to defective vascular structure, 
lack of perfusion of tumour blood vessels, inconsistent flow, and elevated interstitial fluid 
pressure (Jain 2008). However, there is growing evidence that vascular efficiency can be 
improved with anti-angiogenic therapy through the “normalization” process (Jain 2001, 
2005). In Eq. 1.3, the poor delivery of tumor vessels is modeled by the function 
])exp[-(m/ 2limmm . For 2lim m , this function has a maximum at 1m , 
corresponding to the efficient delivery of normal vessels. For 1m , which corresponds 
to tumour vasculature (for example, 1.1~1   and 9.0~2   gives 97.1* m , as 
mentioned in the previous section), the delivery decreases. Finally, 1m  corresponds to 
immature or degraded vessels, resulting again in inefficient nutrient or drug delivery. 
Hence, for a tumor vasculature, decreasing the field m  to values close to one, by the 
administration of an anti-angiogenic agent, results in improved vascular efficiency and 
better delivery of nutrients and chemotherapeutic agents (Kohandel et al. 2007). The 
exponential term therefore accounts for the poor delivery of vasculature as well as the 
increase in the delivery of liposomes and nanocells to tumor cells through normalization. 
One should note that strong dosage of the anti-angiogenic drug may lead to values of m  
less than one, leading to either poor delivery through immature vessels or complete 
regression of the vasculature (Jain 2008). 
 
2.3 Drug release from nanocells and liposomes 
 
Next, we denote by c(x,t) and d(x,t) the concentrations of free anti-angiogenic and 
chemotherapeutic agents released from liposomes and nanocells into the tumor tissue, 
respectively. The temporal and spatial evolution of these fields is modeled by the 
dimensionless equations 
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We shall contrast the four types of treatment tested in the experiments via the index j=1-
4, denoting chemotherapy (NC[D], j=1), anti-angiogenic therapy (L[C], j=2), simple 
liposome encapsulating both (L[CD], j=3), and nanocells (NC[CD], j=4). Free anti-
angiogenesis and chemotherapy agents released from nanocells and liposomes are small 
enough to diffuse through the tumor tissue [first terms in the right side of Eqs. (1.4) and 
(1.5);  ~3D and  
~
4D  are dimensionless diffusion coefficients]. The term dtx mμ ),(~  
describes the re-absorption of free chemotherapy drugs into the blood vessels. We assume 
that no such term is present in the equation for c(x,t) since anti-angiogenic drugs act on 
normal as well as on abnormal blood vessels, which prevents absorption. However, both 
equations involve terms of the form  ~ )( cC  and dD)(~ , which describe the natural 
decay of free drugs. The release of free chemotherapy and anti-angiogenesis agents in 
Eqs. (1.4) and (1.5), i.e., ),(),(~ DCj
DC R , proceeds according to  
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in which the sum runs over all administration times ti. The release profiles RPi, j
(C,D)(t) are 
either identical to zero or satisfy 
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where, as above, the sum runs over all administration times and t f 17days is the longest 
time considered in the experiments by Sengupta et al. (2005). The above condition on the 
release profiles fixes the total amount of drugs released from liposomes and nanocells 
over the time interval considered in the experiments by Sengupta et al. (2005) and, thus, 
ensures a fair comparison of different therapeutic strategies in our model.  
 
Finally, the effects of chemotherapy and anti-angiogenic therapy on cancer cells and 
blood vessels are modeled by 
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where the vertical lines indicate that the above terms are added to Eqs. (1.1) and (1.2), 
respectively. Here, )(~ DA  and )(~ CA  present the strength of chemotherapy and anti-
angiogenic therapy, respectively; ),( txd  and ),( txc  are defined by Eqs. (1.4) and (1.5). 
The details of the above model and its parameterization are discussed below. 
  
 
2.4 Release profiles 
 
To determine the release profiles, )(),(, tRP
DC
ji  for 41j , we first note that NC[D] only 
involves chemotherapy (but does not contain anti-angiogenic therapy), thus 
0)()(1, tRP Ci ; recall that NC[D] is denoted by 1j . Similarly, 0)()(2, tRP Di  since L[C] 
( 2j ) only involves anti-angiogenic therapy. The remaining release profiles should 
ideally be fixed from in vivo release experiments. We expect that the release profiles of 
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combretastatin and doxorubicin in L[CD] are similar to the release profile of 
combretastatin in L[C], i.e., )()()( )(2,
)(
3,
)(
3, tRPtRPtRP
C
i
D
i
C
i   - this is due to the fact that 
for all these cases, drugs are included inside a liposome. Similarly, since all nanocells 
(independently of whether they contain combretastatin or not), have liposome on the 
outer layer, we have )()( )(4,
)(
1, tRPtRP
D
i
D
i  . Thus, we need to determine the functions 
)()(1, tRP
D
i , )(
)(
2, tRP
C
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C
i . The in vitro studies in Sengupta et al. (2005) show 
that the release of doxorubicin from NC[D] is delayed relative to the release of 
combretastatin from the liposome, with an extending time of approximately 4 days for the 
liposome and an extending time of approximately 15 days for the core of the nanocell. On 
that basis we take 
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where ti  8, 10, 12, 14, 16  days are the administration times used in the experiments by 
Sengupta et al. (2005), the constants N1,2,4 are determined from the normalization 
condition, see below Eq. (2), and )(x  is the unit step function (defined by (x) 1 for 
x 1 and (x)  0 otherwise). Assuming that the release profile of L[C] and the liposome 
coating of the nanocell are similar, we can set LL pp   and LL   , in which case Eq. 
(2) implies N2=N4. Based on Sengupta et al. (2005) we take 3.0NCp  and 15NC  
days, and pL  0.1 and 2L  days. For our modified nanocell therapy (see Sec. 3) we 
use the same treatment schedules as for NC[CD] but take 8.0NCp  in Eq. (4) with an 
appropriate normalization factor determined from Eq. (2). This ensures that for all 
combined therapies the nanocells and liposomes release the same total amount of 
combretastatin and doxorubicin. 
 
The function )(ti  in Eq. (1.3) describes the (average) concentration of the liposomes 
and nanocells in the blood vessels. In using the same function )(ti  for liposomes and 
nanocells we assume that, once a therapy has been administered, changes to the drug 
concentration in the blood vessels only result from some natural decay (e.g., adsorption) 
independent of the chemical composition of the particles. Thus, we set 
 
),/)(exp()()( Diii ttttt                 (5) 
 
where, as above, ti  are again the administration times. There is some indication 
(Sengupta et al. (2005), see also Fig. 1) that i (t)  is different for liposomes and 
nanocells, with an increased delivery of nanocells into the tissue surrounding the tumor 
through a mechanism other than vascular normalization. This would further increase the 
effect of NC[CD] relative to L[CD] through an increase in the amount of drugs delivered 
to the tumor. However, in order to allow a direct investigation of the temporal targeting 
mechanism proposed by Sengupta et al. (2005) we take the i (t)  for conventional 
therapies to be the same as for the nanocell treatment and set NCD   .  
 
2.5 Parameterization 
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Free anti-angiogenesis and chemotherapy agents are small particles which can be 
assumed to have diffusion characteristics similar to nutrients such as oxygen, for which 
experimental data is readily available. Thus, we set ˜ D 3  ˜ D 4 in Eqs. (1.4) and (1.5) and 
use a value of ˜ D 3 similar to the diffusion constant of free oxygen in Kohandel et al. 
(2007). As mentioned earlier, the field m(x,t) stands for the average distribution of blood 
vessels (rather than the exact pattern of vasculature), thus the diffusion coefficients for 
drugs (or nutrients) are not of the same order as diffusion from a single blood vessel. 
Moreover, because chemotherapy agents released from the nanocells are transported 
away through blood vessels in the same way for NC[D] and NC[CD], and ˜ D 3  ˜ D 4, we 
use the same re-absorption rate ˜  for all treatments. Similarly as in Kohandel et al. 
(2007) for free oxygen, we assume that the natural decay of c and d is not too strong and, 
hence, that the decay constants ˜ (C )  and ˜ (D) take smaller numerical values than ˜ . 
Furthermore, combretastatin released from the liposome decays faster than doxorubicin 
released from the nanocells (Sengupta et al. 2005) and, thus, we take ˜ (C )  ˜ (D). On the 
other hand, one may expect that doxorubicin released from the liposome during treatment 
with L[CD] decays faster than doxorubicin released from the nanocells. This would 
further decrease the efficiency of L[CD] relative to NC[CD], but to avoid a proliferation 
of parameters we use the same value ˜ (D) for all treatments.  
 
Table 1: Numerical values for the parameters in Eqs. (1) and (3) used in our simulations. In 
addition to the values shown, we use in the dimensionful equations 32.01 D  mm2/day for lung 
cancer and 46.01 D  mm2/day for melanoma, 35.0  day-1 for both melanoma and lung 
cancer (see Sec. 3.1), and a threshold for the detectability of tumor cells 09.0thc  (Kohandel et 
al. 2007). As explained in the main text we have ˜ D 3  ˜ D 4 and ˜ (C ) 100 ˜ (D). The effectiveness 
of chemotherapy and anti-angiogenic therapy are parameterized by 65.1~ )( DA  and 1.0~ )( CA  
for lung cancer, and by 3~ )( DA  and 3.0~ )( CA  for melanoma (see Sec. 3.1). 
 
˜ 1 ˜ D 2 ˜  ˜  ˜  ˜ 2 ˜  mlim ˜ D 3 ˜ (C ) ˜ (C ) ˜ (D) ˜  
1.1 0.005 –1 3 –2 0.9 0.8 2  0.02 1300 3 0.1 8 
 
 
The amount of drugs administered can be included in our model through the values of the 
coefficients ˜ (C ) and ˜ (D) . In the experiments described in Sengupta et al. (2005) 
approximately one hundred times more combretastatin than doxorubicin was injected and, 
hence, we take ˜ (C ) 100 ˜ (D). Moreover, the constants ˜ A (C ) and ˜ A (D)  determine the 
effectiveness of a given therapy and are therefore crucial parameters in our model.  To 
allow a quantitative comparison between the effects of different combined therapies we 
use the same values ˜ A (C ) and ˜ A (D)  for single and combined therapies. It is thereby 
assumed that the effect of a given therapeutic agent is not influenced by the presence or 
absence of another therapeutic agent. The values of all parameters appearing in our model 
are fixed by fitting volume curves for V, L[C], and NC[D] to the corresponding 
experimental results (Sengupta et al. 2005). Table 1 summarizes the parameter values 
used in our simulations (see Appendix for the sensitivity analysis of parameters). The 
results of the combined treatments are then predicted by our model without any further 
assumptions. 
 
While we consider a variety of different interactions in our model, with the aim of not 
excluding any possible mechanism for the success of the nanocell treatment a priori, we 
find that only the three parameters D1, ˜ A 
(C ),  and ˜ A (D)  need to be adjusted to distinguish 
between lung carcinoma and melanoma. Moreover, we also find that for both lung 
carcinoma and melanoma the success of the nanocell treatment relies crucially on the 
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temporal release profiles used in Sengupta et al. (2005), and on the possibility of re-
absorption of chemotherapeutic drugs into the bloodstream (see Sec. 3), which is 
parameterized through ˜ . As in Kohandel et al. (2007) we use a normalized Gaussian 
initial condition for n(x,t) with variance 35.0 , and a random initial condition for 
m(x,t) evenly distributed between zero and one. Zero initial conditions are considered for 
the concentrations of the drugs. All simulations are performed on a cubic grid with 
505050   points and no-flux boundary conditions. 
 
3. Results and Discussion  
3.1 Consistency of model results 
 
To confirm our model, numerical simulations are performed according to the 
experimental protocol of Sengupta et al. (2005) on lung cancer and melanoma (see Fig. 
2). In these experiments, 2.5105 Lewis lung carcinoma cells or 3105 GFP-positive 
BL6/F10 melanoma cells were implanted in male C57/BL6 mice, and treatments started 
when tumors reached 50 mm3 in volume (after about 8 days). The kinetics of tumor 
growth and blood vessel formation, as well as the data points for the control group (V, 
red), are used to estimate the related model parameters for the case of lung cancer (see 
Table 1). The experimental treatment schedules, as well as pharmacokinetics and 
pharmacodynamics of agents, are used in the simulations to fit the data for single 
administration of anti-angiogenic therapy (combretastatin-encapsulated liposomes, L[C], 
brown) and chemotherapy (nanocells containing doxorubicin but lacking combretastatin, 
NC[D], blue). The corresponding curves for melanoma are obtained by modifying three 
model parameters describing the diffusion of cancer cells and the effect of therapeutic 
agents on the vascular network and cancer cells (see Sec. 2). We then perform numerical 
simulations with the estimated parameters to predict the results for the conventional (a 
liposome encapsulating both doxorubicin and combretastatin, L[CD], green) and nanocell 
(NC[CD], purple) approaches for the combination of anti-angiogenic and cytotoxic 
treatments.  
 
As shown in Fig. 2, the numerical results (solid lines) obtained from our 
phenomenological model reproduce the major trends observed in the experiments by 
Sengupta et al. (2005) (points) for lung cancer and melanoma. While the conventional 
combination of combretastatin and doxorubicin only produces a doubling effect 
compared to the single administration of combretastatin or doxorubicin, nanocells clearly 
show a more pronounced effect with the same amount of drugs administered. Our 
simulations strongly support the hypothesis that the increased effect of the nanocell 
treatment is mainly due to the temporal release achieved through nanocells (Sengupta et 
al. 2005), which is from a mathematical perspective the only feature distinguishing 
L[CD] and NC[CD] in our model (see Sec. 2)2. This is discussed further below. 
 
3.2 Synergistic effect of nanocell treatment 
 
Our model predicts the nanocell treatment can produce a combined effect that is greater 
than the sum of its parts through the two different mechanisms illustrated in Fig. 3. First, 
                                                 
2 In Sengupta et al. (2005), the results of the single therapies NC[D] and L[C] were also compared 
to the co-administration of NC[D] and L[C] (NC[D]+L[C]). However, NC[D]+L[C] only showed 
a negligible effect over either of the treatments alone. This is probably due to a limitation on the 
total number of nanocells or liposomes which can be taken up by the tumor tissue at any given 
time. This limitation does not affect any of the other more effective combination strategies 
considered in Sengupta et al. (2005) and, thus, we do not discuss this case in our modeling 
approach. 
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the transient normalization resulting from anti-angiogenic therapy enhances the delivery 
of additional nanocells to the tumor tissue. This in turn increases the effect of the 
subsequent release of chemotherapy. Second, anti-angiogenic therapy can also cut off the 
blood supply to the tumor, which effectively traps the cytotoxic drugs within the tumor 
tissue. Thus smaller amounts of free chemotherapy agents  are transported away from the 
tumor tissue. According to our simulations, the latter mechanism is crucial for obtaining 
the superior results of NC[CD] reported by Sengupta et al. (2005), while normalization 
only brings a small increase in the effectiveness of NC[CD] relative to L[CD]. However, 
as discussed below, normalization can still be employed to further improve the efficacy of 
the nanocell treatment. 
 
As mentioned earlier, our modelling hypothesis is that by adjusting the interplay between 
normalization and the temporal targeting described in Sengupta et al. (2005) an improved 
therapeutic outcome can be achieved. To validate this hypothesis, we modeled different 
release profiles for the nanocell core which delay the secretion of chemotherapy relative 
to anti-angiogenic therapy even further than the release profile considered in the 
experiments of Sengupta et al. (2005) (see Sec. 3). We were careful to adjust the delayed 
release profiles such that over the course of the treatment the same total amount of anti-
angiogenic and chemotherapeutic agents was released as in the combination therapies, 
L[CD] and NC[CD], considered before. Thus, compared to the conventional nanocell 
therapy, with our modified release profiles more chemotherapeutic agents are released by 
nanocells administered at early times, but correspondingly fewer chemotherapeutic drugs 
are released by nanocells administered at later times. 
 
The simulation results indicate that with the adjusted release kinetics a substantial 
improvement in the efficacy of the nanocell treatment can be achieved (see the black 
curves in Fig. 2). As illustrated in Fig. 3, this improved result is due to a combination of 
normalization, which is mainly effective in the early stages of the therapy and increases 
the fraction of nanocells delivered to the tumor tissue at early times, and the vascular 
shutdown induced by anti-angiogenic therapy, which decreases the fraction of nanocells 
delivered at later times and traps the chemotherapeutic agents within the tumor 
tissue. Our modified release profiles take advantage of these two effects and lead 
to better coordination between the arrival of nanocells in the tumor tissue and the 
release of anti-angiogenic and chemotherapeutic agents. Thus, our simulations 
suggest that by means of a judicious timing of normalization and the trapping of 
chemotherapeutic agents in the tumor tissue through the release of combretastatin, 
a better therapeutic outcome can be achieved. 
 
In summary, mathematical models can be used to simulate various therapeutic 
scenarios and aid in hypothesis testing “in silico,” and conversely to guide 
experimental research. Following the very successful experimental results of 
Sengupta et al. (2005), and experimental and clinical studies on the normalization 
process of tumor vasculature (Tong et al. 2004, Willett et al. 2004, Winkler et al. 
2004), we have developed a mathematical  formulation that captures the 
qualitative picture proposed by Sengupta and co-workers. Further the model has 
been used to test our hypothesis for the effective combination of anti-angiogenic 
therapy and chemotherapy. On the basis of this model we find that the 
dramatically improved therapeutic effect of the nanocell treatment demonstrated 
by Sengupta et al. (2005) primarily results from the trapping of chemotherapeutic 
agents, rather than an increase in the number of nanocells delivered to the tumor 
through normalization. Moreover, we find that through an adjustment of the release 
kinetics for chemotherapy it may be possible to substantially improve the efficacy of the 
nanocell treatment. As a result of our promising computational results, it seems clear that 
more experimental and preclinical data are required to further validate this strategy for 
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improved therapeutic outcome. In particular, our model results suggest that nanocells 
with a longer delay in the secretion of chemotherapy relative to anti-angiogenic therapy 
(compared to the release profile considered in the experiments of Sengupta et al. (2005)) 
may further increase the efficiency of the treatment. Our computational approach could 
be also used to design nanocells for other types of cancers, and to quantitatively 
determine promising release profiles.  
 
Appendix 
 
In this appendix, we study the effects of small variations in the values of the parameters 
on the model outcome. To study parameter sensitivity, we calculate the effect of small 
changes of the parameters on final tumor volume (at day 17). We determine the percent 
change in the final tumor volume when the model parameters are perturbed from their 
estimated values by 5% (de Pillis et al. 2005). Fig. A1 shows the results for the case of 
combination of therapies using nanocells and liposomes, i.e. NC[CD] and L[CD], in lung 
cancer. One should note that changing ˜ (C ) 100 ˜ (D) has the same effect as varying ~ ; 
in addition, the parameters ~ , ~ , and ~  are not changed as they are responsible for the 
creation of the vascular network (see main text). The results indicate that the parameters 
1
~  and ~  contribute most significantly to the final tumor volume; however, these 
contributions are smaller in L[CD] compared to NC[CD]. 
 
 
 
Figure A1: Sensitivity analysis for L[CD] and NC[CD] in Lewis lung carcinoma. Each set 
comprising four color-coded columns corresponds to the parameter indicated directly below on the 
x-axis. 
 
To investigate whether the trends obtained from the model for different treatments are 
robust upon change of these parameters, we performed the numerical simulations for the 
cases that 1
~  and ~  are increased by 5% while the rest of the parameters were held 
fixed. As shown in Fig. A2, these variations do not affect the trends illustrated in Fig. 2a. 
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Figure A2: The tumor volume obtained with a 5% increase in (a) 1
~  and (b) ~  for Lewis lung 
carcinoma. 
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Figure captions 
 
Figure 1: Confocal micrographs of tissue cross sections harvested from tumor-bearing 
mice at 24 h post-injection with imaging-nanocells. Mice were injected with nanocells 
labeled with semiconductor nanocrystals (quantum dots) to monitor the distribution and 
leakage from the vessels in the tumor and normal tissues. The sections were 
immunostained for von Willebrand Factor (vWF) to delineate vasculature. Images were 
captured using a Zeiss LSM510 confocal microscope at 512×512 pixel resolution. The 
sections were excited with a 488nm laser, and emission was absorbed at FITC (vWF) and 
Rhodamine (QD) wavelengths. The nanocells were found to be spatially restricted within 
normal vasculature as seen in the overlap (yellow) of the red and green signal in the 
merge images but extravasate out from the tumor vasculature at 24h as seen by the 
predominantly red signal (merge). 
 
Figure 2: Curves for the tumor volume of (a) lung cancer and (b) melanoma obtained with 
no treatment (V), nanocells containing only doxorubicin (NC[D]), liposomes containing 
only combretastatin (L[C]), liposomes with combretastatin and doxorubicin (L[CD]), 
nanocells with combretastatin and doxorubicin (NC[CD]) and nanocells with 
combretastatin and doxorubicin but with a delayed release of doxorubicin (NC[CD] and 
pNC  0.8). The solid curves are obtained by integrating Eqs. (1.1)–(1.5) in Sec. 2 and 
the data points are taken from the experiments by Sengupta et al. (2005). The same total 
amount of drugs is released by liposomes and nanocells for the combined therapeutic 
strategies, which corresponds to double the amount released for NC[D] and L[C] 
individually.  
 
Figure 3: Mechanisms for the temporal targeting of tumor cells and neovasculature. (a) 
Nanocells are delivered to the tumor tissue through the neovasculature and rapidly release 
anti-angiogenic agents. (b) The vascular collapse leads to the trapping of the 
chemotherapeutic agents within the tumor tissue and thereby prevents re-absorption into 
the bloodstream. According to our mathematical model this is the principal mechanism 
responsible for the superior results of the nanocell treatment found by Sengupta et al. 
(2005). (c) The normalization of tumor blood vessels produced by the anti-angiogenic 
therapy leads to a transient “window of opportunity” (Jain 2005) during which the 
delivery of nanocells into the tumor tissue is enhanced. (d) Our model suggests that 
through a judicious timing of the release profiles the interplay between normalization and 
vascular collapse can be utilized to improve the efficacy of the nanocell treatment. 
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